Similar Articles |
|
Pharmaceutical Executive June 1, 2011 |
2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead. |
Pharmaceutical Executive October 1, 2005 Jeffrey D. Abbey |
Considering Intangibles Biotech partnerships among scientists, academic institutions, and pharma companies provide many challenges, including identifying the right partners, developing strong relationships to overcome hurdles, and dealing with cultural differences in an increasingly global market. |
Pharmaceutical Executive June 1, 2012 |
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead. |
Chemistry World August 23, 2012 Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. |
Pharmaceutical Executive January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
Pharmaceutical Executive May 1, 2007 Waseem Noor |
Toolkit: How To Be a Better Partner Big pharmas and little biotechs have been getting hitched for years. Now it's time to add a little innovation to the relationship. Three new rules will keep the game exciting. |
Pharmaceutical Executive July 10, 2014 William Looney |
Pharm Exec's 2014 Dealmakers Outlook As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead. |
Pharmaceutical Executive May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
Pharmaceutical Executive September 1, 2010 |
Looking Beyond the Patent Cliff Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP. |
Entrepreneur September 2003 David Newton |
Now Showing Win partners by letting them see what you're made of -- with a "portfolio" of your patented technology. |
The Motley Fool April 14, 2011 Frank Vinluan |
Biogen Idec Inks Biotech Blood Products Research Deal With Amunix The exclusive, worldwide research collaboration agreement calls for both companies to jointly conduct preclinical research. |
HBS Working Knowledge October 4, 2004 Loren Gary |
The Profit Power of Partnerships For many top companies, revenue from alliances is growing more than 20 percent annually. What goes into a successful alliance? The critical first step is picking the right partner. |
Pharmaceutical Executive April 10, 2014 Christini & Kaitin |
Regional Trends in Bioinnovation Investment Can the Cambridge model be duplicated? |
CFO April 1, 2011 Josh Hyatt |
Grab Your Partner(s) With the economy's choppy waters calming down, companies are finding that a partnership strategy born of necessity can also be a valuable part of a growth strategy. |
Pharmaceutical Executive May 1, 2009 |
The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. |
Entrepreneur April 2008 Guy Kawasaki |
Tying the Knot Partnering is an art, so make sure everyone sees eye to eye with these 8 tips. |
Pharmaceutical Executive July 1, 2011 Todd C. Davis |
Seeing the Fire Behind the Smoke While crafting license agreements involves all of the tactical tradeoffs expected in a negotiating dynamic, one should try to pay attention to these 10 licensing pitfalls. |
Pharmaceutical Executive June 1, 2006 Paul Kidwell |
Public Relations: Targeting Partners PR can facilitate business partnerships between biotechnology and pharmaceutical companies by targeting messages to key players. |
Pharmaceutical Executive March 1, 2013 Henninger & Feldstein |
Safeguarding the Value of Patent Assets As small biotech firms test the water in partnerships with Big Pharma, the best calling card is a well-framed strategy on intellectual property. |
IndustryWeek February 1, 2009 Jill Jusko |
IP Assets Deserve Their Due Diligence in M&A Transactions Companies believe that intellectual property assets will become more important to overall M&A activity in the next five years. |
D-Lib December 2007 Kaufman & Ubois |
Good Terms - Improving Commercial-Noncommercial Partnerships for Mass Digitization OCLC Programs and Research engaged Intelligent Television to study the partnership agreements between cultural institutions and for-profit companies for the mass digitization of books and other media. This report presents the findings of that study. |
Pharmaceutical Executive November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
Information Today June 26, 2014 |
Thomson Reuters and Royal Philips Team Up to Protect IP The partnership is designed to protect intellectual property, business intelligence, and foster product innovation. |
Pharmaceutical Executive May 1, 2011 Thompson & Twait |
High-Risks to High Reward According to Eli Lilly, managing alliances requires more than good people skills. |
Pharmaceutical Executive April 1, 2012 |
Leading from the South India's most prominent scientist sets a new agenda for pharma in emerging markets. |
CIO June 1, 2003 John Edwards |
Creative Management Intellectual property asset management tools help businesses get a handle on mind-based products. |
Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
Pharmaceutical Executive September 1, 2006 Nick Rogerson |
Slow Deal Flow? 10 Quick Fixes for Getting Business Development Back on Track |
Registered Rep. November 1, 2002 Jonathan Arfa |
Breaking Up Is Hard to Do Brokers partner up for a variety of reasons. Some kind of contract is needed when a partnership between members of a team of brokers is formed, whether it be between a senior broker and junior colleagues or just between two seasoned brokers. Brokers should consider this contract seriously. |
Pharmaceutical Executive September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
Chemistry World December 1, 2010 Mike Brown |
Glasgow IP giveaway The University of Glasgow is giving away its intellectual property for free in a move designed to maximize dissemination of knowledge and increase commercial collaboration. |
Pharmaceutical Executive December 1, 2010 Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Pharmaceutical Executive January 1, 2009 Stan Bernard |
Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms. |
Bio-IT World October 2006 Eric K. Neumann |
The Advantages of a Drug Safety Commons Once a Drug Safety Commons has been established, a variety of derivative applications will be developed that can access as well as update the information in organized ways and used by industry researchers internally. |
CIO August 28, 2009 Howell & Perera |
How to Protect Your Legal Rights When Sharing IT Services To get the benefits from shared services, you need to address the risks to your company's intellectual property. |
Knowledge@Wharton |
Encouraging the Development of Drugs for Poor, not Just Rich, Nations The current system rewards research into diseases that afflict rich countries, but creating new medicines for the rest of the world and finding ways to pay for them will demand new partnerships, according to panelists at the recent conference "Pharmaceutical Innovation in a Global Economy." |
HBS Working Knowledge November 13, 2006 Sean Silverthorne |
Science Business: What Happened to Biotech? The biotech industry has underperformed expectations, caught in the conflicting objectives and requirements between science and business. |
ONLINE November 2001 Peter Vanderheyden |
Divide-and-Conquer Patent Research A revolutionary strategy to optimize your time and increase your influence... |
Managed Care February 2002 Ira Studin |
Reframing the Pharmaceutical Manufacturer/Health Plan Relationship in Managed Care It is suggested that health plans address "total cost-of-care savings" in their budget process, and the pharmaceutical manufacturers establish a "consultative service function" in their managed care divisions... |
The Motley Fool June 29, 2006 Dan Caplinger |
Starting a Small Business: Partnerships Establishing your business as a partnership offers flexibility but potential liability. |
Financial Advisor March 2005 David L. Lawrence |
Merging Options Five steps may help you avoid pitfalls and make your financial advisory practice merger a success. |
Chemistry World July 10, 2015 Angeli Mehta |
Business unable to access knowledge locked up in universities A bewildering array of organizations and schemes to support collaborative research between businesses and universities in the UK is leading to frustration and confusion, and needs to be simplified. |
Bio-IT World June 17, 2004 Stephanie McRae |
Expatriate Your Patents Intellectual property rights, especially patents, are often the principal source of value and revenue for biotechnology companies. You can save a boatload of tax money shipping your IP rights overseas. |
Chemistry World November 1, 2011 Sarah Houlton |
A Shot in the Arm for Drugs for Neglected Diseases A new consortium of public and private sector partners has been launched by the World Intellectual Property Organization. Its aim is to share intellectual property that may help find drugs for malaria, tuberculosis and other neglected tropical diseases. |
IndustryWeek May 18, 2011 |
How to Build a Better Supplier Partnership Don't ignore the key concepts of trust, time and mutual benefits. |
Commercial Investment Real Estate Jul/Aug 2003 John Mangham |
Partnerships Can Use These Methods to Protect 1031 Gains Property owners wishing to dispose of appreciated assets often use Internal Revenue Code Section 1031 exchanges to defer capital gains taxes. However, partnerships wishing to execute exchanges face unique challenges, particularly when individuals in the partnership have diverging investment goals or want to cash out. |
Chemistry World July 15, 2014 Emma Stoye |
Public--private research partnerships to tackle Europe's big problems The European Union will invest euro 7.3 billion in seven newly launched public -- private partnerships as part of its Horizon2020 research funding program. |
InternetNews May 4, 2005 Michael Singer |
Microsoft Expands IP Program to SMBs Entrepreneurs can choose from 20 technologies from Microsoft's R&D portfolio. Microsoft Intellectual Property Ventures complements its policy of licensing to larger corporations and governments. |
Entrepreneur March 2006 Marc Diener |
Two's Company Before you start negotiating a business partnership, take these three key steps. |
Registered Rep. October 30, 2014 Philip Palaveev |
To Ensemble or Not To Ensemble Thousands of advisors are negotiating the combination of their practices with others in order to create scale, leverage each other's skills, gain resources, and tackle succession. |